BBNX vs BIO Stock Comparison

BIO currently leads BBNX in this stock comparison, with AIQ scores of 73 vs 54. The clearest difference is value.

Market data as of Nov 18, 2026 market close· AIQ score gap 19 points
BBNX
Healthcare
vs
BIO
Healthcare
BBNX
Beta Bionics, Inc.
Price
$14.33
Day move
-2.65%
AIQ Score
54/100
Best edge
Balanced
Sector
Healthcare
BIO
Bio-Rad Laboratories, Inc.
Leads
Price
$370
Day move
+3.34%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare

What is the main difference between BBNX and BIO?

BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Beta Bionics, Inc. vs Bio-Rad Laboratories, Inc.

Data as of Nov 18, 2026· market close· Healthcare· Coverage 61/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 10/10

BIO leads

BIO leads by 19 AIQ points, primarily on Value and Risk Resilience, and the lead has widened from 16 points over 30 sessions.

Stable: 5 of 5 evidence groups support BIO, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 5 of 5Comparison trend: Strengthening
BBNX

Beta Bionics, Inc.

AIQ Score
54/100
AIQ Edge Score
5/10
BIO

Bio-Rad Laboratories, Inc.

Leads
AIQ Score
73/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors BIO over BBNX, 73 versus 54 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value and risk resilience. BIO also shows the stronger technical structure relative to its 50-day moving average. 5 of 5 covered evidence groups favor BIO today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. BIO lead: Strengthening — the AIQ differential moved from 16 to 19 points over 30 sessions. BIO leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare Beta Bionics, Inc. and Bio-Rad Laboratories, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

BBNX
-39.4%
BIO
+3.2%

Price return comparison

Growth of $10,000, price only

BBNX $6,064 · BIO $10,315

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare BBNX and BIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BBNX advantage
0
BIO advantage
  • Value39 vs 80
    BIO +41
  • Risk Resilience36 vs 74
    BIO +38
  • Quality53 vs 61
    BIO +8
  • Momentum72 vs 79
    BIO +7

5 of 5 evidence groups favor BIO. BIO’s edge is concentrated in value and risk resilience.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

BBNX+1 AIQ

Largest factor move: Momentum +2

No signal started or stopped since the prior session; its 4 active signals are unchanged.

BIO0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon

BIO's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BBNX and BIO both carry a full feed there.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BIO

BIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BIO

BIO on combined revenue and EPS growth.

Value

BIO

BIO on the peer-relative Value factor, by 41 points.

Momentum

BIO

BIO on the Momentum factor, by 7 points.

Lower downside

BIO

BIO on Risk Resilience, by 38 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBBNXBIONote
Implied upside to target+71.7%—Level
Target dispersion+56.9%—Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering153Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 5 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBIO54 vs 73
FundamentalsBIOon balanceEPS growth 1.9% vs 23.3%; TTM ROE -6.1% vs 6%; gross margin 58.6% vs 51.3%; operating margin -72.7% vs 4.6% — BIO takes 3 of 4 decided legs, not all of them
ValuationBIOValue 39 vs 80
TechnicalsBIOPrice vs 50-day -22.4% vs -0.7%; vs 200-day 10.8% vs 15.6%
Risk ResilienceBIORisk Resilience 36 vs 74
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BBNX and BIO and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 19 points. (supports the conclusion holding)
  • 5 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

BIO lead: Strengthening — the AIQ differential moved from 16 to 19 points over 30 sessions.

Jun 1BBNX leads above the line · BIO leads belowNov 18
Today
BIO +19
54 vs 73
7 sessions ago
BIO +20
55 vs 75
30 sessions ago
BIO +16
56 vs 72
90 sessions ago
BIO +16
57 vs 73

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BBNXConflicted

1 bullish / 1 bearish / 2 neutral, conflicted

Only BBNX

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
BIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only BIO

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.

BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BBNXDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.65%, AIQ +1 points).

BIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BBNX closes the Value gap — currently 41 points behind, the largest single contributor to BIO's edge.
  2. 2BBNX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

BIO leads on balance
MetricBBNXBIO
Revenue growth (YoY)10.9%0.8%
EPS growth (YoY)1.9%23.3%
Gross margin58.6%51.3%
Operating margin-72.7%4.6%
Return on equity (TTM)-6.1%6%
Debt to equity0.020.18

Performance

BIO leads 4 of 6 windows
MetricBBNXBIO
1 week (5 sessions)4.6%-4%
1 month (20 sessions)0.4%3.6%
3 months (63 sessions)-6.5%3.1%
6 months (126 sessions)73.6%48%
Year to date-46.1%20.9%
1 year (252 sessions)-41.7%11.9%

Technicals

BIO has the stronger structure
MetricBBNXBIO
RSI (14)45.545.4
ADX (14)1312.9
Price vs 50-day-22.4%-0.7%
Price vs 200-day10.8%15.6%
Volatility (1M, annualized)109.6%31.4%

Risk

BIO is the more resilient
MetricBBNXBIO
Beta1.470.73
Sharpe ratio-0.160.47
Sortino ratio-0.220.69
Max drawdown-72.3%-27.2%
Current drawdown-48.7%-6.1%
Annualized volatility84.7%36.2%
Value at risk (95%)-7.4%-3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BBNX or BIO?

On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against BBNX's 54. The edge comes from value and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BBNX or BIO the better buy right now?

BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Stable — 5 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor BIO over BBNX?

The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 41 points; BIO leads Risk Resilience by 38 points; BIO leads Quality by 8 points. BIO leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by BBNX simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, BBNX or BIO?

Analyst price targets imply +71.7% upside for BBNX and not covered for BIO. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BBNX or BIO?

BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 41 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BBNX or BIO?

BIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BBNX or BIO?

BIO on the Momentum factor, by 7 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BBNX or BIO?

BIO is the more resilient of the two, so the other name carries the higher downside risk. BIO on Risk Resilience, by 38 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BBNX more profitable than BIO?

The profitability evidence is mixed: gross margin 58.6% vs 51.3%; operating margin -72.7% vs 4.6%; ttm roe -6.1% vs 6%. BBNX leads on one measure and BIO on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is BIO's lead over BBNX getting stronger or weaker?

BIO lead: Strengthening — the AIQ differential moved from 16 to 19 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the BBNX vs BIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BBNX closes the Value gap — currently 41 points behind, the largest single contributor to BIO's edge; BBNX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BBNX and BIO?

BBNX: 1 bullish / 1 bearish / 2 neutral, conflicted. BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BBNX is Golden Cross Active (bullish, long horizon). On BIO it is Golden Cross Active (bullish, long horizon).

Compare BBNX and BIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.